Secarna Pharmaceuticals

🌍 Secarna at BIO-Europe 2024 in Stockholm! Konstantin Petropoulos will attend #BIOEurope, Europe’s premier life sciences partnering event! With the continued growth and success of our #AI -empowered oligonucleotide discovery and development platform, we look forward to connecting with industry leaders to explore new collaboration opportunities and showcase our latest advancements in #oligonucleotidetherapeutics. If you’re attending BIO-Europe, don’t miss the chance to reach out via the partnering program and connect with us to discuss how our innovative solutions have the potential to transform untreatable conditions into treatable ones, changing the future of medicine together with you. Connect with us via the 1on1 partnering system 👉: https://lnkd.in/dMsTNtrX #BIOEurope #Innovation #Networking 

🔊We are thrilled to share that Andre Maaske, Research Scientist at Secarna, will deliver the keynote presentation at the upcoming 2nd Annual MarketsandMarkets™ ImmunoBio Series conference in Freiburg, Germany, on October 15 at 9 am CET! 🧬 In his presentation entitled “Neuropilin-1 (NRP1) as novel target for antisense oligonucleotides (ASOs) to treat patients with solid tumors”, Andre will share insights into the latest advancements in antisense oligonucleotide therapeutics, specifically focusing on their application in the exciting field of immuno-oncology. With his expertise in next-generation ASO technologies, this is a presentation you won’t want to miss! 👉 More details on the event here: https://lnkd.in/e6jiU9bB #ImmunoBioSeries2024 #AntisenseTherapeutics #Innovation

🔊 Secarna CEO Alexander Gebauer, M.D., Ph.D. and CBO Konstantin Petropoulos, Ph.D., MBA, will attend #BioJapan in Yokohama, Japan, October 9-11, 2024. 🌏We are excited to attend the largest biotech partnering event in Asia for the first time. This incredible opportunity allows us to showcase our latest advancements in the discovery and development of best-in-class oligonucleotide therapeutics and to connect with thought leaders in biotechnology, pharmaceuticals and healthcare in Asia.   We look forward to seeing you.   #BiotechConferences #InnovationInHealthcare #Oligonucleotides

Meet us at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada from October 6 - 9, 2024! Secarna’s Chief Scientific Officer, Frank Jaschinski, will present our latest work with MLKL-specific ASOs. MLKL plays a central role in an inflammatory cell death pathway termed “necroptosis” and has evolved as an attractive therapeutic target for the treatment of a wide range of diseases including acute kidney injury caused by ischemia reperfusion. Join us October 7 for our poster presentation P121 on “Targeting the necroptosis pathway by downregulating MLKL expression with antisense oligonucleotides”. Don’t miss the chance to stop and engage with Frank about how our innovative ASO therapies are addressing unmet medical needs! 👉 Learn more about the conference here: https://lnkd.in/gXsgtqD5 #ots24 #antisensetherapies #networking #KidneyDisease

This week’s 24th Annual Biotech in Europe Forum #Sachs_BEF was a success. Besides the opportunity to connect with investors, thought leaders and innovators from around the globe, our CBO Konstantin Petropoulos participated in the panel Platform Technologies & Novel Therapeutics: Diverse Business Models alongside with Joachim Vogt, Director Search & Evaluation International, AbbVie Inc., Kristian Tryggvason, Founder & CEO, Alder Therapeutics AB, Olav Zilian, MD, PhD, EMBA, Senior Financial Analyst, Pictet Group and Stephane Degove, CEO, Atamyo Therapeutics SAS. The panelists agreed that platforms – such as our oligonucleotide discovery platform – are helpful to grow biotech companies and generally trigger investor interests. For pharmaceutical companies, they are a valuable tool to create novel products for patients that urgently need them.

🌟 Conference season is here, and we couldn't be more excited! We are pleased to announce that we will be attending several scientific conferences as well as partnering events in September. They provide a fantastic opportunity for us to share our latest advancements in the discovery and development of best-in-class oligonucleotide therapeutics and to connect with thought leaders and innovators from around the world. Here's where you can meet us: 📌 6th Annual #InflammasomeTherapeuticsSummit in Boston, MA, USA Presentation: "Leveraging the Power of ASOs to Target the Expression of NLRP3 for Enhanced Specificity of Inflammasome Inhibition" 🗓 September 11, 12:00 pm 👩🔬 Julia Hinterdobler, Ph.D., Scientist at Secarna Pharmaceuticals 📌 LSX - partnering for Life Science eXecutives World Congress USA in Boston, MA, USA 🗓 September 11 – 12 👨🔬 Konstantin Petropoulos, Ph.D., MBA, CBO of Secarna Pharmaceuticals 📌 Congress of the ESMO - European Society for Medical Oncology Oncology, #ESMO24 in Barcelona, Spain 🗓 September 13 - 17 Meet our CEO Alexander Gebauer, M.D., Ph.D. at the conference! 📌 24th Annual Biotech in Europe Forum #SACHS_BEF in Basel, Switzerland Panel: "Platform Technologies & Novel Therapeutics: Diverse Business Models" 🗓 September 25, 3:50 pm - 4:45 pm 👨🔬 Konstantin Petropoulos, Ph.D., MBA, CBO of Secarna Pharmaceuticals We look forward to seeing you! #BiotechConferences #InnovationInHealthcare #Oligonucleotides

🔬 Exciting news! Our latest #researchpaper has just been published in Nucleic Acid Therapeutics (Mary Ann Liebert, Inc.)! In the publication entitled "Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides," our team conducted a comprehensive investigation into the toll-like receptor 9 (TLR9)-dependent immunostimulatory potential of locked nucleic acid antisense oligonucleotides (LNA ASOs). We found that TLR9-mediated unspecific immune stimulation, a frequent undesired side effect in earlier generations of ASOs, can also occur with LNA ASOs. Our results further indicated that TLR9-dependent immunostimulatory potential is an individual feature of an ASO that must be investigated on a case-by-case basis. However, the application of sophisticated test systems allows for the identification of ASOs targeting different genes, achieving potent target knockdown without TLR9 stimulation. Read the full article here (open access): https://lnkd.in/dmeebVgq 📚 Big shout-out to our first author Irene Riera Tur, PhD and all co-authors: Julia Hinterdobler, Andre Maaske, Anne Sadewasser, Monika Schell, Janani Sekar, Sven Michel, Richard Klar, and Frank Jaschinski.   #drugdevelopment #science

🎉 We are thrilled to announce that we've hit 1,000 followers on LinkedIn!   A heartfelt thank you to each of you for your incredible support, engagement, and valuable connections.    This milestone does not only reflect our growth here at LinkedIn, but also as a company. Since #Secarna Pharmaceuticals’ founding in 2015, our focus has been on antisense therapeutics, and with increasing focus on targeted antisense oligonucleotides (ASOs) developed through our advanced AI-powered #ASO platform. Our work and that of others active in the field has established ASOs as a vital class of therapeutic molecules.   What’s next? We currently see a rapidly growing number of development candidates: According to a July 2024 GlobalData Plc search, there are more than 100 ASO candidates in Phase 2 or 3 clinical development and we anticipate a significant increase in ASO #therapies launching in the coming years. With this momentum, Secarna is aiming for an exciting future, aiming to translate our preclinical findings into clinical data and developing new and effective targeted treatments - for the benefit of patients around the world. Here's to more learning, networking, and growth! 🙌 #Biotech #Innovation #LifeSciences

We are happy to announce that our CBO Konstantin Petropoulos will attend BayOConnect on July 2 - 3 in Munich. On site, he will be presenting a poster entitled “Translating an AI-powered, next generation antisense oligonucleotide (ASO) discovery platform towards a first-in-class drug candidate: SECN-15 targeting Neuropilin-1 as novel checkpoint inhibitor” in which he will show an overview of Secarna’s unique ASO technology platform as well as an update on our lead program for immuno-oncology, SECN-15.   Make sure to pass by and chat with Konstantin to get to know Secarna Pharmaceuticals' ASO-targeted approach for difficult-to-treat diseases.   #Biotech #Innovation #Networking #LifeSciences

How is Secarna Pharmaceuticals addressing undruggable targets? Our CEO Alexander Gebauer sat with Janelle Hart from Citeline to discuss how we employ our artificial intelligence (AI)-powered ASO discovery and development platform to benefit patients across multiple indications.     Our ASO platform plays a crucial role in developing tailor-made and targeted ASOs, as it is designed to select and profile ASOs against challenging or historically undruggable targets. In synergy with our own bioinformatics and screening systems, they are the backbone of both, comprehensive testing and target-specific functional assays that lead to the development of effective and safe ASOs that target the cells, tissues, and organs of interest for the respective projects.    Curious to learn more about our first-in-class assets, as well as our future goals a? Read the full article (paywall) here: https://lnkd.in/e3p96Geq